Low Residue Diet Study in Mitochondrial Disease
NCT03388528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2019-10-11
Summary
Slow movement of patients guts is referred to as intestinal dysmotility, and is increasingly recognised as a debilitating manifestation of mitochondrial disease both in adults and children.
To date, symptoms of slow gut movements have been managed with laxatives and drugs that increase movement of the guts with variable results. A low residue diet is a form of low fibre diet (\<10g fibre per day) that is used to minimise symptoms of poor movement of the guts. This reduces fecal volume and bulk, and hence gut workload, ensuring limited bowel activity and colonic rest. It has been shown to be well accepted in other conditions associated with slow gut movements. However, its role in patients with mitochondrial disease is unknown. The investigators are particularly interested in:
* Does a low residue diet (low fibre) cause a change in the number of stools per week and stool consistency?
* Is a low residue diet tolerated well and easy to comply with?
* Does a low residue diet reduce gut symptoms of abdominal pain, bloating, and constipation?
* Does a low residue diet improve quality of life and disease burden?
* Does a low residue diet affect the bacteria in the gut?
* Can we prove by X-ray that movement of food through the gut is slowed in patients with mitochondrial disease, and whether a low residue diet alters the speed of movement of food through the gut?
* Can a low residue diet change patients physical activity levels?
* Does a low reside diet change dietary patterns and food intake?
* Does a low residue diet alter anthropometrics, such as weight, body mass index and waist to hit ratio?
* Can a low residue diet improve kidney and liver function and lipid profile in blood samples?
The investigators hope that by looking at these areas that a low residue diet may be able to improve patients slow gut movements, health, quality of life and disease burden.
Conditions
- Mitochondrial Diseases
Interventions
- DIETARY_SUPPLEMENT
-
Low Residue Diet Intervention
All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
Sponsors & Collaborators
-
Newcastle-upon-Tyne Hospitals NHS Trust
collaborator OTHER -
Newcastle University
lead OTHER
Principal Investigators
-
Grainne S Gorman, MD · Newcastle University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-08
- Primary Completion
- 2019-02-07
- Completion
- 2019-02-07
Countries
- United Kingdom
Study Locations
More Related Trials
-
Mitophagy and Autophagy in Elderly Subjects
NCT02472340 ·Status: COMPLETED
-
A Study of Bezafibrate in Mitochondrial Myopathy
NCT02398201 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease
NCT00457314 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies
NCT03351270 ·Status: COMPLETED ·Phase: NA
-
Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients
NCT03973203 ·Status: COMPLETED ·Phase: NA
-
Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy
NCT00004770 ·Status: COMPLETED ·Phase: NA
-
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)
NCT01521728 ·Status: COMPLETED ·Phase: NA
-
Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients
NCT05287958 ·Status: COMPLETED
-
Intestinal Microbiome Transplant in ALS
NCT07017946 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders
NCT03728777 ·Status: COMPLETED ·Phase: NA
-
Mechanisms and Treatment of Exercise Intolerance and Persistent Fatigue in Spinal Muscular Atrophy
NCT05518773 ·Status: COMPLETED
-
New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.
NCT03984708 ·Status: COMPLETED ·Phase: NA
-
The U.K. NorthStar Clinical Network
NCT06711692 ·Status: NOT_YET_RECRUITING
-
Exercise Capacity of Patients with Dermatomyosis
NCT03293615 ·Status: TERMINATED ·Phase: NA
-
Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease
NCT02154711 ·Status: COMPLETED
-
Fatigue in Patients With Amyotrophic Lateral Sclerosis
NCT04468191 ·Status: WITHDRAWN ·Phase: NA
-
Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis
NCT03293394 ·Status: COMPLETED ·Phase: NA
-
Calf Muscle Strength in Mitochondrial Diseases
NCT02678637 ·Status: COMPLETED
-
Brown Adipose Tissue in ALS
NCT03150290 ·Status: COMPLETED ·Phase: NA
-
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
NCT04802707 ·Status: RECRUITING ·Phase: PHASE2
-
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
NCT03789175 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
NCT02895789 ·Status: COMPLETED
-
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
NCT02255422 ·Status: COMPLETED ·Phase: PHASE2
-
Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies
NCT02448667 ·Status: COMPLETED ·Phase: NA
-
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
NCT01948102 ·Status: COMPLETED